1. A12First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (NEO)adjuvant trastuzumab. (26th September 2015) Authors: Vaglica, M.; Vaglica, M.; Lambertini, M.; Ferreira, A.; Poggio, F.; Puglisi, F.; Sottotetti, F.; Montemurro, F.; Poletto, E.; Pozzi, E.; Risi, E.; Lai, A.; Zanardi, E.; Sini, V.; Ziliani, S.; Minuti, G.; Mura, S.; Grasso, D.; Ferrarini, I.; Pronzato, P. Journal: Annals of oncology Issue: Volume 26(2015)Supplement 6 Page Start: vi6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1863 First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (neo)adjuvant trastuzumab. (September 2015) Authors: Vaglica, M.; Lambertini, M.; Ferreira, A.; Poggio, F.; Puglisi, F.; Sottotetti, F.; Montemurro, F.; Poletto, E.; Pozzi, E.; Risi, E.; Lai, A.; Zanardi, E.; Sini, V.; Ziliani, S.; Minuti, G.; Mura, S.; Grasso, D.; Ferrarini, I.; Pronzato, P.; Del Mastro, L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S286 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. (October 2017) Authors: Alù, M.; Ancona, C.; Andreis, D.; Bajardi, E.; Benedetto, C.; Berardi, R.; Bordin, E.; Butti, C.; Capri, G.; Cicchiello, F.; Cocciolone, V.; Dester, M.; D'Onofrio, L.; Febbraro, A.; Ferrarini, I.; Fotia, V.; Gervasi, E.; Guaitoli, G.; Licata, L.; Liscia, N. Journal: Breast Issue: Volume 35(2017) Page Start: 115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗